2 Information about dostarlimab

Marketing authorisation indication

2.1 Dostarlimab (Jemperli) is indicated as 'monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for dostarlimab.


2.3 The list price of dostarlimab is £5,887.33 per 500 mg vial. The company has a commercial arrangement. This makes dostarlimab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.